| ŠIMEK, Matěj, Kristina NEŠPOROVÁ, Anna KOCURKOVÁ, Tereza FOGLOVÁ, Gabriela AMBROŽOVÁ, Vladimír VELEBNÝ, Lukáš KUBALA a Martina HERMANNOVÁ. How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy. Carbohydrate Polymers. Oxford: Elsevier Ltd., 2021, roč. 263, July, s. "117927", 10 s. ISSN 0144-8617. Dostupné z: https://dx.doi.org/10.1016/j.carbpol.2021.117927. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1769457,
author = {Šimek, Matěj and Nešporová, Kristina and Kocurková, Anna and Foglová, Tereza and Ambrožová, Gabriela and Velebný, Vladimír and Kubala, Lukáš and Hermannová, Martina},
article_location = {Oxford},
article_number = {July},
doi = {http://dx.doi.org/10.1016/j.carbpol.2021.117927},
keywords = {Hyaluronan; Pharmacokinetics; Molecular weight; Stable isotope; Metabolism},
language = {eng},
issn = {0144-8617},
journal = {Carbohydrate Polymers},
title = {How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy},
url = {https://doi.org/10.1016/j.carbpol.2021.117927},
volume = {263},
year = {2021}
}
TY - JOUR
ID - 1769457
AU - Šimek, Matěj - Nešporová, Kristina - Kocurková, Anna - Foglová, Tereza - Ambrožová, Gabriela - Velebný, Vladimír - Kubala, Lukáš - Hermannová, Martina
PY - 2021
TI - How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy
JF - Carbohydrate Polymers
VL - 263
IS - July
SP - "117927"
EP - "117927"
PB - Elsevier Ltd.
SN - 01448617
KW - Hyaluronan
KW - Pharmacokinetics
KW - Molecular weight
KW - Stable isotope
KW - Metabolism
UR - https://doi.org/10.1016/j.carbpol.2021.117927
N2 - There is inconsistent information regarding the size effects of exogenously given hyaluronan on its in vivo fate. The data are often biased by the poor quality of hyaluronan and non-ideal labelling strategies used for resolving exogenous/endogenous hyaluronan, which only monitor the label and not hyaluronan itself. To overcome these drawbacks and establish the pharmacokinetics of intravenous hyaluronan in relation to its Mw, 13C-labelled HA of five Mws from 13.6–1562 kDa was prepared and administered to mice at doses 25−50 mg kg–1. The elimination efficiency increased with decreasing Mw. Low Mw hyaluronan was rapidly eliminated as small hyaluronan fragments in urine, while high Mw hyaluronan exhibited saturable kinetics and complete metabolization within 48 h. All tested Mws exhibited a similar uptake by liver cells and metabolization into activated sugars. 13C-labelling combined with LC–MS provides an excellent approach to elucidating in vivo fate and biological activities of hyaluronan.
ER -
ŠIMEK, Matěj, Kristina NEŠPOROVÁ, Anna KOCURKOVÁ, Tereza FOGLOVÁ, Gabriela AMBROŽOVÁ, Vladimír VELEBNÝ, Lukáš KUBALA a Martina HERMANNOVÁ. How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy. \textit{Carbohydrate Polymers}. Oxford: Elsevier Ltd., 2021, roč.~263, July, s.~''117927'', 10 s. ISSN~0144-8617. Dostupné z: https://dx.doi.org/10.1016/j.carbpol.2021.117927.
|
